Analysts See $-1.15 EPS for Insmed (INSM); Riverhead Capital Management Upped Kohl’s (KSS) Stake

Kohl's Corporation (NYSE:KSS) Logo

Riverhead Capital Management Llc increased Kohl’s Corp (KSS) stake by 37.04% reported in 2018Q3 SEC filing. Riverhead Capital Management Llc acquired 27,940 shares as Kohl’s Corp (KSS)’s stock declined 21.21%. The Riverhead Capital Management Llc holds 103,380 shares with $7.71 million value, up from 75,440 last quarter. Kohl’s Corp now has $10.98 billion valuation. The stock increased 0.59% or $0.39 during the last trading session, reaching $66.51. About 2.59 million shares traded. Kohl's Corporation (NYSE:KSS) has risen 30.59% since February 14, 2018 and is uptrending. It has outperformed by 30.59% the S&P500. Some Historical KSS News: 23/03/2018 – KOHL’S OUTLOOK TO STABLE FROM NEGATIVE BY FITCH; 13/03/2018 – KOHLS CORP KSS.N : CREDIT SUISSE INITIATES WITH OUTPERFORM, $72 TARGET PRICE; 11/05/2018 – KOHLS CORP – WATSON WILL CONTINUE TO SERVE AS A DIRECTOR OF COMPANY; 27/03/2018 – Kohl’s CEO says ‘big idea’ behind Amazon partnership is driving traffic; 22/05/2018 – Kohl’s Raises EPS Guidance; 22/05/2018 – Kohl’s 1Q Net $75M; 21/04/2018 – DJ Kohl’s Corporation, Inst Holders, 1Q 2018 (KSS); 16/04/2018 – KOHLS – INCREASED COMBINED PRINCIPAL AMOUNT OF NOTES & DEBENTURES CO MAY BUY IN PREVIOUSLY ANNOUNCED CASH TENDER OFFER FROM $300 MLN TO ABOUT $500 MLN; 27/03/2018 – Cramer also sits down with the CEOs of Kohl’s and Zoetis; 16/04/2018 – Kohl’s Demonstrates Positive Social Impact in 2017 CSR Report

Analysts expect Insmed Incorporated (NASDAQ:INSM) to report $-1.15 EPS on February, 22.They anticipate $0.30 EPS change or 35.29% from last quarter’s $-0.85 EPS. After having $-1.14 EPS previously, Insmed Incorporated’s analysts see 0.88% EPS growth. The stock increased 0.19% or $0.05 during the last trading session, reaching $26.02. About 573,921 shares traded. Insmed Incorporated (NASDAQ:INSM) has declined 42.91% since February 14, 2018 and is downtrending. It has underperformed by 42.91% the S&P500. Some Historical INSM News: 02/05/2018 – Insmed 1Q Research and Development Expenses $30.1M; 29/03/2018 – INSMED SEES GETTING SIX-MONTH PRIORITY REVIEW; 02/05/2018 – Insmed 1Q Loss $68.5M; 23/04/2018 – Insmed Closes Above 50-Day Moving Average: Technicals; 02/05/2018 – INSMED 1Q CASH & CASH EQUIVALENTS $686.6M; 29/03/2018 – lnsmed Submits New Drug Application to FDA for ALIS in NTM Lung Disease Caused by MAC; 02/05/2018 – Insmed: Actively Preparing for Potential Pdt Launch of ALIS in 4Q 2018; 16/05/2018 – INSMED INC – PDUFA ACTION DATE SET FOR SEPTEMBER 28, 2018; 29/03/2018 – INSMED SUBMITS NEW DRUG APPLICATION TO FDA FOR ALIS IN NTM LUNG DISEASE CAUSED BY MAC; 23/04/2018 – DJ Insmed Incorporated, Inst Holders, 1Q 2018 (INSM)

More notable recent Insmed Incorporated (NASDAQ:INSM) news were published by: which released: “Options Traders Expect Huge Moves in Insmed (INSM) Stock – Nasdaq” on January 25, 2019, also with their article: “Looking Behind Insmed’s Recent Revenue Beat – Seeking Alpha” published on January 21, 2019, published: “Goldman bullish on Insmed in premarket analyst action – Seeking Alpha” on January 17, 2019. More interesting news about Insmed Incorporated (NASDAQ:INSM) were released by: and their article: “Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) – PRNewswire” published on February 04, 2019 as well as‘s news article titled: “Top 5 Small-Cap Winners And Losers, Week Of Jan. 7 – Yahoo! Finance News” with publication date: January 16, 2019.

Investors sentiment decreased to 0.82 in 2018 Q3. Its down 0.38, from 1.2 in 2018Q2. It worsened, as 21 investors sold Insmed Incorporated shares while 35 reduced holdings. 21 funds opened positions while 25 raised stakes. 76.71 million shares or 1.99% less from 78.27 million shares in 2018Q2 were reported. Hudson Bay Capital Mngmt L P has invested 0.02% in Insmed Incorporated (NASDAQ:INSM). Alliancebernstein Ltd Partnership holds 114,000 shares or 0% of its portfolio. Bnp Paribas Arbitrage holds 4,393 shares or 0% of its portfolio. Moreover, Barclays Public Lc has 0% invested in Insmed Incorporated (NASDAQ:INSM) for 36,281 shares. Alps Advisors Incorporated accumulated 136,333 shares. Stifel Finance invested 0% of its portfolio in Insmed Incorporated (NASDAQ:INSM). Us State Bank De owns 482 shares. 22,370 were reported by Essex Mgmt Limited Liability. Voya Invest Limited Liability Company invested in 1.16 million shares or 0.05% of the stock. Geode Mngmt Ltd Liability Com stated it has 0% of its portfolio in Insmed Incorporated (NASDAQ:INSM). Adage Prtnrs Gp Ltd Liability Company owns 1.25 million shares or 0.06% of their US portfolio. Vanguard Group Inc has 6.80 million shares for 0.01% of their portfolio. Dekabank Deutsche Girozentrale reported 33,500 shares stake. Zurcher Kantonalbank (Zurich Cantonalbank) reported 4,662 shares. Cubist Systematic Strategies Limited Liability Company invested in 7,706 shares or 0.01% of the stock.

Since November 1, 2018, it had 4 insider buys, and 2 insider sales for $610,461 activity. SHAROKY MELVIN MD also bought $320,211 worth of Insmed Incorporated (NASDAQ:INSM) shares. 3,000 Insmed Incorporated (NASDAQ:INSM) shares with value of $47,907 were bought by Adsett Roger. Another trade for 15,700 shares valued at $249,600 was made by Lewis William on Thursday, November 1. Another trade for 16,085 shares valued at $253,993 was made by ENGELSEN STEINAR J on Thursday, November 1. ALTOMARI ALFRED also sold $123,750 worth of Insmed Incorporated (NASDAQ:INSM) shares.

Among 5 analysts covering Insmed (NASDAQ:INSM), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Insmed had 5 analyst reports since October 1, 2018 according to SRatingsIntel. The firm has “Outperform” rating given on Monday, October 1 by Credit Suisse. The rating was maintained by Citigroup on Tuesday, December 4 with “Neutral”. Morgan Stanley maintained Insmed Incorporated (NASDAQ:INSM) on Monday, October 1 with “Overweight” rating. The stock of Insmed Incorporated (NASDAQ:INSM) earned “Buy” rating by Goldman Sachs on Thursday, January 17.

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company has market cap of $2.01 billion. The company's lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It currently has negative earnings. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension.

Among 4 analysts covering Kohl’s (NYSE:KSS), 1 have Buy rating, 1 Sell and 2 Hold. Therefore 25% are positive. Kohl’s had 5 analyst reports since August 22, 2018 according to SRatingsIntel. The firm earned “Neutral” rating on Wednesday, November 21 by Citigroup. The stock of Kohl's Corporation (NYSE:KSS) has “Underweight” rating given on Thursday, August 23 by Morgan Stanley. The firm has “Neutral” rating by Credit Suisse given on Wednesday, November 21. Credit Suisse maintained Kohl's Corporation (NYSE:KSS) rating on Wednesday, August 22. Credit Suisse has “Neutral” rating and $78 target.

More notable recent Kohl's Corporation (NYSE:KSS) news were published by: which released: “Kohl’s and WW to partner – Seeking Alpha” on January 29, 2019, also with their article: “Under Armour Stock Rallies After Earnings … But Why? –” published on February 13, 2019, published: “Kohl’s: Expect Another Dividend Increase In 2019 – Seeking Alpha” on January 16, 2019. More interesting news about Kohl's Corporation (NYSE:KSS) were released by: and their article: “Can These 3 Hated Department Store Stocks Recover? – Motley Fool” published on January 15, 2019 as well as‘s news article titled: “The Retail Apocalypse May Be Claiming Another Victim – The Motley Fool” with publication date: February 10, 2019.

Riverhead Capital Management Llc decreased Ishares Core S&P 500 Etf (IVV) stake by 5,248 shares to 17,631 valued at $5.16M in 2018Q3. It also reduced Morgan Stanley (NYSE:MS) stake by 48,650 shares and now owns 48,878 shares. Wyndham Worldwide Corp (NYSE:WYN) was reduced too.

Kohl's Corporation (NYSE:KSS) Institutional Positions Chart